T Harrer
Overview
Explore the profile of T Harrer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
771
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitt C, Hoefsmit E, Fangmeier T, Kramer N, Kabakci C, Vera Gonzalez J, et al.
Cancer Immunol Immunother
. 2023 Aug;
72(11):3475-3489.
PMID: 37606856
Background: Immune checkpoint inhibitors (ICI) substantially improve outcome for patients with cancer. However, the majority of patients develops immune-related adverse events (irAEs), which can be persistent and significantly reduce quality...
2.
Lee J, Ostalecki C, Zhao Z, Kesti T, Bruns H, Simon B, et al.
EBioMedicine
. 2018 Jan;
28:151-161.
PMID: 29331674
No abstract available.
3.
Borte M, Krivan G, Derfalvi B, Marodi L, Harrer T, Jolles S, et al.
Clin Exp Immunol
. 2016 Sep;
187(1):146-159.
PMID: 27613250
A highly concentrated (20%) immunoglobulin (Ig)G preparation for subcutaneous administration (IGSC 20%), would offer a new option for antibody replacement therapy in patients with primary immunodeficiency diseases (PIDD). The efficacy,...
4.
Fatkenheuer G, Jessen H, Stoehr A, Jung N, Jessen A, Kummerle T, et al.
HIV Med
. 2016 May;
17(6):453-9.
PMID: 27166295
Objectives: PEPDar compared the tolerability and safety of ritonavir-boosted darunavir (DRV/r)-based post-exposure prophylaxis (PEP) with the tolerability and safety of standard of care (SOC). The primary endpoint was the early...
5.
Hofstra L, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al.
Clin Infect Dis
. 2015 Dec;
62(5):655-663.
PMID: 26620652
Background: Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen....
6.
La Mancusa A, Rech J, Harrer T, Knorr H, Bergua A
Klin Monbl Augenheilkd
. 2011 Apr;
228(7):639-40.
PMID: 21452106
No abstract available.
7.
Siahmakoun A, Harrer T
Appl Opt
. 2010 Sep;
32(35):7281-4.
PMID: 20861946
We present a dynamic Schlieren system that uses optical phase conjugation in a photorefractive crystal. The theoretical description of the system predicts that the square of the phase change in...
8.
Stellbrink H, Baldus S, Behrens G, Bogner J, Harrer T, Hoffmann C, et al.
Eur J Med Res
. 2010 Feb;
15(1):1-12.
PMID: 20159665
This manuscript is communicated by the German AIDS Society (DAIG) (www.daignet.de). It summarizes a series of presentations and discussions during a workshop on immune activation due to HIV infection. The...
9.
Jansen K, Brockmeyer N, Hahn M, Kaul I, Fenske S, Rausch M, et al.
Eur J Med Res
. 2009 Sep;
14(10):415-25.
PMID: 19748848
Objective: As its central basis for research, the Competence Network for HIV/AIDS (KompNet) established a nationwide cohort study on HIV-positive patients being in medical care in Germany. In this paper,...
10.
Leipe J, Hueber A, Rech J, Harrer T
AIDS Care
. 2008 Jul;
20(7):863-7.
PMID: 18608059
This case study describes a 44-year-old, chronically non-adherent, HIV-infected male with relapsing, life threatening toxoplasmic encephalitis (TE) and other recurring opportunistic infections. Non-adherence resulted in critical illness, suppressed CD4 lymphocyte...